• Greater Twin Cities: 715.294.4371

  • Search

Purchase Exemestane (Aromasin) tablets online

How and where to order Aromasin (Exemestane) 25 mg tablets online:

Prices: from $3.87 per pill
Discount: 5% coupon: 5OFF (Shop 1), 10% coupon: MSD10 (Shop 2)
Forms: Exemestane (Aromasin) 25 mg tablets
Quantity: 30, 60, 90, 120 pills
Type: Aromasin generic, Exemestane brand, Xtane brand
Payment: Visa, Mastercard, AmEx, E-Check (ACH), Bitcoin
Delivery: Standard airmail and trackable courier service
Shipping: Worldwide, including USA, UK, Europe, Canada, Australia

Exemestane (trade names include Aromasin, Aromasil, Exedrol, Liquid Aromasin, Mestane, Nateran, Xtane) is an anticancer medication from aromatase inhibitors pharmacological group. This medicine is indicated for the treatment of breast cancer in postmenopausal women. It is often prescribed for women whose cancer has progressed even after radiation, surgery, or other cancer medications have been tried without success. Aromasin works by lowering estrogen level and helping to slow or stop the growth of cancer with estrogen receptors (ER-positive breast cancers). Exemestane is also used for bodybuilding to raise luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels; to counteract gynecomastia as well as fat and water retention due to testosterone doping; in medical researchs, and for other purposes.

Aromasin (Exemestane) tablets 25 mg

Related medications:

  • Aminoglutethimide (Cytadren)
  • Anastrozole (Arimidex)
  • Bromocriptine (Parlodel)
  • Butylscopolamine (Buscopan)
  • Cabergoline (Dostinex)
  • Capecitabine (Xeloda)
  • Clomiphene (Clomid)
  • Danazol (Danocrine)
  • Desogestrel, Ethinyl Estradiol (Desogen)
  • Dydrogesterone (Duphaston)
  • Eflornithine (Vaniqa)
  • Estradiol (Estrace)
  • Estrogens conjugated (Premarin)
  • Formestane (Lentaron)
  • Gestrinone (Dimetrose)
  • Hydroxyurea (Droxia)
  • Ibandronate (Boniva)
  • Imatinib (Gleevec)
  • Letrozole (Femara)
  • Medroxyprogesterone (Cycrin)
  • Norethisterone (Aygestin, Norlutate)
  • Progesterone (Prometrium)
  • Raloxifene (Evista)
  • Sildenafil Citrate (Female Viagra)
  • Tadalafil (Female Cialis)
  • Tamoxifen (Nolvadex)
  • Vorozole (Vorozol)

    Pharmacological and medical categories:

  • Anticancer drugs
  • Antiestrogens
  • Antineoplastic agents
  • Cytotoxic chemotherapy
  • Hormonal chemotherapy
  • Medications for the treatments of breast cancer
  • Medicines to treat ER-positive cancers
  • Oncology medicines
  • Orally active aromatase inhibitors
  • Pharmaceutical products for sports and bodybuilding purposes
  • Steroidal aromatase inhibitors
  • Women's health

    ATC codes:

  • L - Antineoplastic and immunomodulating agents
  • L02 - Endocrine therapy
  • L02B - Hormone antagonists and related agents
  • L02BG - Aromatase inhibitors
  • L02BG06 - Exemestane

    ICD-10 codes:

  • Malignant neoplasm of breast - C50

    Indications and usage:

    Aromasin (Exemestane) is an aromatase inhibitor indicated for:

  • adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to Aromasin for completion of a total of five consecutive years of adjuvant hormonal therapy.
  • treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.

    Dosage and administration:

    Recommended dose: one 25 mg exemestane tablet once daily after a meal.


    Clinical trials have been conducted with exemestane given as a single dose to healthy female volunteers at doses as high as 800 mg and daily for 12 weeks to postmenopausal women with advanced breast cancer at doses as high as 600 mg. These dosages were well tolerated. There is no specific antidote to overdosage and treatment must be symptomatic. General supportive care, including frequent monitoring of vital signs and close observation of the patient, is indicated.

    A male child (age unknown) accidentally ingested a 25-mg tablet of exemestane. The initial physical examination was normal, but blood tests performed 1 hour after ingestion indicated leucocytosis (WBC 25000/mm3 with 90% neutrophils). Blood tests were repeated 4 days after the incident and were normal. No treatment was given.

    In mice, mortality was observed after a single oral dose of exemestane of 3200 mg/kg, the lowest dose tested (about 640 times the recommended human dose on a mg/m2 basis). In rats and dogs, mortality was observed after single oral doses of exemestane of 5000 mg/kg (about 2000 times the recommended human dose on a mg/m2 basis) and of 3000 mg/kg (about 4000 times the recommended human dose on a mg/m2 basis), respectively.

    Convulsions were observed after single doses of exemestane of 400 mg/kg and 3000 mg/kg in mice and dogs (approximately 80 and 4000 times the recommended human dose on a mg/m2 basis), respectively.

    Dosage forms and strengths:

    Aromasin (Exemestane) tablets 25 mg.


    Patients with a known hypersensitivity to the drug or to any of the excipients.

    Warnings and precautions:

  • Reductions in bone mineral density (BMD) over time are seen with exemestane use.
  • Routine assessment of 25-hydroxy Vitamin D levels prior to the start of aromatase inhibitor treatment should be performed.
  • Embryo-fetal toxicity: can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception.

    Adverse reactions, side effects:

  • Early breast cancer: adverse reactions occurring in >= 10% of patients in any treatment group were hot flushes, fatigue, arthralgia, headache, insomnia, increased sweating. Discontinuation rates due to AEs were similar between Aromasin and tamoxifen. Incidences of cardiac ischemic events (myocardial infarction, angina, and myocardial ischemia) were exemestane 1.6%, tamoxifen 0.6%. Incidence of cardiac failure: Aromasin (Exemestane) 0.4%, tamoxifen 0.3% (6, 6.1).

  • Advanced breast cancer: most common adverse reactions were mild to moderate and included hot flushes, nausea, fatigue, increased sweating, increased appetite.

    To report suspected adverse reactions, contact Pfizer Inc. or your local FDA.

    Drug interactions:

    Strong CYP 3A4 inducers: concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. Increase the Aromasin (Exemestane) dose to 50 mg.

    Use in specific populations:


    Advise not to breastfeed.

    Pediatric use

    Safety and effectiveness in pediatric patients have not been established.

    Hepatic impairment

    The AUC of exemestane was increased in subjects with moderate or severe hepatic impairment (Childs-Pugh B or C). However, based on experience with exemestane at repeated doses up to 200 mg daily that demonstrated a moderate increase in non life-threatening adverse reactions, dosage adjustment does not appear to be necessary.

    Renal impairment

    The AUC of exemestane was increased in subjects with moderate or severe renal impairment (creatinine clearance < 35 mL/min/1.73 m2). However, based on experience with exemestane at repeated doses up to 200 mg daily that demonstrated a moderate increase in non life-threatening adverse reactions, dosage adjustment does not appear to be necessary.

    Pregnancy categories:

  • C - Australia
  • D - United States (Positive evidence of risk)

    Salts and other forms:

  • Exemestane Base

    Synonyms, international and chemical names:

  • 6-Methylenandrosta-1,4-diene-3,17-dione
  • 6-Methyleneandrosta-1,4-diene-3,17-dione
  • Androsta-1,4-diene-3,17-dione, 6-methylene-
  • Eksemestaani
  • Eksemestan
  • Exemestaan
  • Exemestan
  • Exemestano
  • Exemestanum

    Brands, generics, trade names:

  • Apo-Exemestane - Apotex
  • Aromasil - Pfizer
  • Aromasin - Pfizer, LF Asia Distribution, O.P.D. Laboratories, The Glory Medicina, Zuellig Pharma
  • CO Exemestane - Cobalt Pharmaceuticals
  • Exedrol - Balkan Pharmaceuticals
  • Exemestan - Actavis, Generics UK, Hexal, Stada
  • Exemestane - Accord Healthcare, Arrow Generiques, Mylan, Roxane Laboratories, Sandoz, Teva, Zentiva
  • Exemestano - Cinfa Laboratorios, Kern Pharma, Normon Laboratorios, Sandoz, Teva
  • Liquid Aromasin - Pfizer
  • Maseren - Pharmadiet
  • Mestane - Douglas Pharmaceuticals, Farma Group
  • Nateran - Synthon
  • Symex - SymPhar
  • Xtane - Natco Pharma


  • Exemestane main article on Wikipedia: https://en.wikipedia.org/wiki/Exemestane
  • Exemestane compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/Exemestane
  • Exemestane on DrugBank: https://go.drugbank.com/drugs/DB00990
  • Exemestane FAQ on MedlinePlus (revised 01/15/2018): https://medlineplus.gov/druginfo/meds/a607006.html
  • Aromasin (Exemestane) tablets drug label on DailyMed (revised May 30, 2018): https://dailymed.nlm.nih.gov/dailymed/lookup...
  • Cadila Exemestane tablets drug label on DailyMed (revised August 26, 2020): https://dailymed.nlm.nih.gov/dailymed/lookup...
  • Exemestane for sale on Pharma Doctor (revised February 2022): https://pharma-doctor.com/exemestane.html
  • Exemestane containing drugs on Drugs-About.com: https://drugs-about.com/ing/exemestane.html
  • Aromasin (Exemestane) tablets for oral use official prescribing and patient information from the U.S. FDA (revised 05/2018): https://www.accessdata.fda.gov/drugsatfda_docs/label...
  • Aromasin (Exemestane) tablets for oral use official prescribing and patient information from Pfizer pharmaceutical company (revised 05/2018): https://labeling.pfizer.com/ShowLabeling.aspx?id=523
  • Aromasin (Exemestane) 25 mg tablets official website.: https://www.aromasin.com/
  • Aromasin (Exemestane) 25 mg coated tablets package information leaflet on Medicines.org.uk (revised 08/2020): https://www.medicines.org.uk/emc/files/pil.5520.pdf
  • Exedrol (Exemestane) 25 mg tablets product information from Balkan Pharmaceuticals (revised 24/08/2019): https://balkan-pharmaceuticals.org/pharmaceuticals/exedrol-25-mg/
  • Mestane (Exemestane) 25 mg film-coated tablets product information from MedSafe (revised 02 May 2018): https://www.medsafe.govt.nz/profs/Datasheet/m/mestanetab.pdf

    Revised: February 2022

Preclinical Testing Solutions
Throughout the
Product Innovation Cycle.